Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Affiliations

Comment

Christoph Wanner et al. N Engl J Med. 2016.

. 2016 Nov 3;375(18):1801-2.

doi: 10.1056/NEJMc1611290.

No abstract available

Comment on

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. N Engl J Med. 2016. PMID: 27299675 Clinical Trial.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wakisaka M. Wakisaka M. N Engl J Med. 2016 Nov 3;375(18):1799-1800. doi: 10.1056/NEJMc1611290. N Engl J Med. 2016. PMID: 27806237 No abstract available.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Pareek A, Chandurkar N, Naidu K. Pareek A, et al. N Engl J Med. 2016 Nov 3;375(18):1800. doi: 10.1056/NEJMc1611290. N Engl J Med. 2016. PMID: 27806238 No abstract available.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Parving H-H, Lambers-Heerspink H, de Zeeuw D. Parving H-H, et al. N Engl J Med. 2016 Nov 3;375(18):1800-1. doi: 10.1056/NEJMc1611290. N Engl J Med. 2016. PMID: 28106974 No abstract available.